FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The 'Fc Protein and Glyco-engineered Antibodies Market' report features an extensive study on the current and future potential of Fc engineered antibodies. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry. In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025.

Further, within the antibody therapeutics industry, engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, have garnered significant interest over the past few years. The modifications (such as glycoengineering, protein engineering or isotype chimerism) in the Fc region of an antibody have shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule.

Moreover, several Fc engineering technologies enable the suppression of the effector functions in certain pathways, and are being actively exploited for development of anti-cancer antibodies.

Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms, which, in turn, has led to the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and significant investment into the innovator companies.

The consistent research efforts in this domain have translated into the emergence of two blockbuster drugs, namely Gazyva (for Chronic Lymphocytic Leukemia) and POTELEGIO (for Sezary syndrome) and several other Fc engineered antibody products, including MargenzaT, MONJUVI and SKYRIZIT that received approval in the past few years.

More recently, in 2021, two Fc engineered antibodies, namely Sotrovimab and Etesevimab, got approved for the treatment of COVID-19. Further, there are several drugs in the development pipeline, which are being investigated by various small and established pharmaceutical companies.

The promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to give the required impetus to the push pipeline products to higher stages of development, and commercialization. We believe that the market is likely to evolve at a commendable pace over the next decade.

One of the key objectives of the report was to estimate the existing and future growth potential of Fc protein and glyco-engineered antibodies market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030.

Key Questions Answered

• Who are the leading industry and non-industry players engaged in the development of Fc protein and glyco-engineered antibodies?
• Which are the key disease indications being targeted by Fc engineered antibodies?
• Which partnership models are commonly adopted by stakeholders engaged in this domain?
• Which geographies are the most active in conducting clinical trials on Fc protein and glyco-engineered antibodies?
• Which are the leading administering institutes supporting the research related to Fc protein and glyco-engineered antibodies?
• How has the intellectual property landscape in this market evolved over the years?
• Which key factors are likely to influence the evolution of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Companies Mentioned

• AbbVie
• Academia Sinica
• AGC Biologics
• Agenus
• Airway Therapeutics
• Akesobio
• Albert Einstein College of Medicine
• Alexion Pharmaceuticals
• Amgen
• argenx
• AstraZeneca
• BeiGene
• BIOCAD
• Biogen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Canadian Cancer Trials Group
• Cantargia
• CATO SMS
• Celgene
• Celldex Therapeutics
• Chia Tai Tianqing Pharmaceutical
• Chinese Academy of Sciences
• Chugai Pharmaceuticals
• CSL Behring
• Daiichi Sankyo
• Dana-Farber Cancer Institute
• Duke University
• Eli Lilly
• Emory University
• EVERSANA
• Five Prime Therapeutics
• Fountain Biopharma
• Genentech
• Genmab
• German CLL Study Group
• Gilead Sciences
• Glycotope
• GlaxoSmithKline
• Guangzhou Development District
• Hoosier Cancer Research Network
• Horizon Therapeutics
• Humanigen
• I-Mab Biopharma
• Immunicum
• Incyte
• Janssen
• Junshi Biosciences
• Kolltan Pharmaceuticals
• Kyowa Kirin
• Leland Stanford Junior University
• LEO Pharma
• Ludwig Institute for Cancer Research
• MD Anderson Cancer Center
• MacroGenics
• Memorial Sloan Kettering Cancer Center
• Menarini
• MorphoSys
• National Institute of Allergy and Infectious Diseases (NIAID)
• National Institutes of Health Clinical Center
• NGM Biopharmaceuticals
• Novartis
• Oneness Biotech
• ONK Therapeutics
• PAREXEL
• Patheon
• Provention Bio
• Roche
• Samsung Biologics
• Sanofi
• Seagen
• Seoul National University Hospital
• Sino Biopharmaceutical
• SYNIMMUNE
• TG Therapeutics
• The Rockefeller University
• Tillotts Pharma
• Tiziana Life Sciences
• TRIANNI
• United BioPharma
• University of California, Los Angeles (UCLA)
• University of Leicester
• University of Maryland
• University of Pennsylvania
• University of Texas
• University of Virginia
• Viela Bio
• Vir Biotechnology
• Visterra
• Vitaeris
• Washington University
• WuXi Biologics
• Xencor
• Zai Lab
• Zymeworks

For more information about this report visit https://www.researchandmarkets.com/r/uh7mfy

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900